CBD bulk ingredient supplier FarmCeutica Wellness has signed a two-year deal to supply North East England company Wellacy with product for its white label CBD ranges.
Gateshead-based Wellacy provides over 3,000 unique formulations for CBD vape, cosmetics and nutritional supplement brands and products.
FarmCeutica has spent over £2m on its UK Novel Food applications and – as one of the few companies to undertake its own in-house toxicity trials – is well-placed to secure FSA Novel Food Authorisation.
With the UK Novel Food deadline just a few weeks away the partners believe the deal will help them capitalise on the significant market opportunities it brings for compliant CBD companies.
It positions Wellacy as an entry-point facilitator for new brands looking to enter the CBD market.
Wellacy Labs CEO Mark Cooper said “We are delighted to announce our partnership with FarmCeutica. It was the natural choice for us to partner, our combined synergies and values toward science and the industry overall make this the perfect relationship.
“One of the most important points is we can continue to support and grow industry leading brands whilst assisting start-ups to confidently enter the space. We are certain this relationship will allow us to be more competitive and pass the benefits directly onto our clients”.
Julius Bond, Managing Director at Scunthorpe-based FarmCeutica, said: “FarmCeutica is delighted to have added Wellacy Labs to our prestigious international customer base.
“Wellacy Labs’ commitment to the highest certified product quality, mirrors FarmCeutica’s uncompromising ‘science first – from seed to sales’ strategy, which sets the industry standard for exclusively greenhouse and indoor grown pharmaceutical and nutraceutical cannabinoid products.
Animal Toxicity Trial
“Wellacy Labs’ progressive perspective for white label product development complimented by FarmCeutica’s scientifically controlled seed genetics, cultivation, refining and extraction of cannabinoid ingredients, delivers the ultimate premium product for consumer customers.”
FarmCeutica takes a ‘science first’ approach to the industry with control of seed genetics, cultivation to its own standard operating protocols in 5.4m sq ft of contracted greenhouses.
Its refining and extraction to exacting pharmaceutical and nutraceutical standards under the quality control of its own Chief Scientific Officer.
Its customers include white-label CBD manufacturers, pharmaceutical companies and those making APIs.
In September last year it launched a trial on 15 different animal species with the aim of satisfying regulators that CBD is safe.
The $2m trial on mice, rats, pigs and other species was undertaken in collaboration with the GLP Neuroscience Center in Kentucky.